CD8A and neoplasm: Furthermore, PRAME silencing reduced the frequency of CD8+ T cells expressing the immune checkpoints PD-1, LAG-3, and VISTA, indicating that PRAME tumor expression significantly impairs the PD-L1/PD-1 axis by dysregulating both the ligand and its receptor [26].